CA
NZ
UK
AU
IND
US
The TrumpRx platform—officially launched in February 2026—has quietly become the federal government’s most visible lever in the fight against escalating prescription drug costs. On Monday the White House added more than 600 generic medicines to the site, positioning it as a one-stop shop where …
Merck & Co. (NYSE: MRK) and Kelun-Biotech’s experimental antibody–drug conjugate sacituzumab tirumotecan (sac-TMT) has become the first globally successful phase 3 therapy in endometrial cancer, a malignancy where new systemicOptionsremain scarce. The TroFuse-005 study met both co-primary endpoints—overall survival (OS) and progression-free survival (PFS)—according …
The U.S. Food and Drug Administration’s decision on May 5th—announced jointly by Daiichi Sankyo Co. (TYO: 4568) and AstraZeneca plc (LSE: AZN)—marks the first time an antibody-drug conjugate has been approved for early-stage HER2-positive breast cancer in both the neoadjuvant (pre-surgery) and adjuvant (post-surgery) …
Roche (SIX: ROG) has taken a calculated step to broaden access to its antiviral flu treatment, Xofluza (baloxavir marboxil), by inking a voluntary licensing deal with the Geneva-based Medicines Patent Pool (MPP). The agreement—announced on May 18th, 2026—grants generic manufacturers in 129 low- and …
A First-in-Class Drug That Could Reshape Hypertension Treatment
Bristol Myers Squibb (NYSE: BMY) has vaulted to the front of the pharmaceutical industry’s AI adoption curve by signing a multi-year strategic agreement with Anthropic to deploy its Claude Enterprise platform across global workflows. The deal—unveiled on Wednesday—marks a decisive shift from fragmented, department-level …
UCB (Euronext Brussels: UCB) has deepened its claim on the psoriasis market after releasing detailed data from a head-to-head psoriatic-arthritis trial showing Bimzelx’s superiority over AbbVie’s (NYSE: ABBV) Skyrizi. In the study, 49% of patients treated with Bimzelx achieved a 75% reduction in disease-activity …
A federal jury in Philadelphia delivered a historic blow to Takeda Pharmaceutical Company Limited on May 21st, ordering the Japanese drugmaker to pay $885m for orchestrating what prosecutors described as an illegal “pay-for-delay” scheme around its constipation drug Amitiza—used by roughly 3m Americans annually. …
Key HighlightsPharmaMarketingis pivoting from broad campaigns to targeted, consent-based engagement—amid a 1.7m strong HCP audience (Fierce Pharma, 2026)Audio marketing—including podcasts—is gaining traction as a way to cut through information saturation for healthcare professionalsBrands are shifting from promotional messaging to partnerships built on trust, per …
Geopolitical Risk Drives the Rebound
Please wait processing your request...